Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, is advancing its lead candidate CNM-Au8 to address neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease. CNM-Au8 targets the nicotinamide adenine dinucleotide (NAD+) pathway, crucial for mitochondrial functions, including energy production and redox homeostasis, aiming to restore and protect neurological function.
The potential impact of CNM-Au8 is significant given the prevalence of these disorders. Nearly 2 million Americans are affected by ALS, MS, or Parkinson’s disease. In the U.S., approximately 5,000 individuals are diagnosed with ALS each year, with around 30,000 people currently living with the disease.
The global therapeutics markets for neurodegenerative diseases are projected to grow substantially. This growth is driven by the increasing prevalence of these conditions, a rising geriatric population, and the emergence of new therapies. Clene's preparation for Phase 3 trials of CNM-Au8 in MS and ALS positions the company at the forefront of this promising market.
For more information on Clene's initiatives and their innovative treatment approach, visit Clene Inc. and Read More>>.
